Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
CD34 selected T-cell depleted allogeneic SCT(New York Medical College) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
CD34 selected T-cell depleted allogeneic SCT(New York Medical College): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical.
8 min read
PR1 peptide antigen vaccine(The University of Texas M.D. Anderson Cancer Center) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
PR1 peptide antigen vaccine(The University of Texas M.D. Anderson Cancer Center): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers.
8 min read
AFYX-004 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
AFYX-004: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
Rapcabtagene autoleucel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
Rapcabtagene autoleucel: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market.
8 min read
LPM-3770164 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
LPM-3770164: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
TVI Head & neck-1 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
TVI Head & neck-1: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position.
8 min read
Efgitasialase alfa Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
Efgitasialase alfa: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position.
8 min read
BB-101(National Cheng Kung University) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
BB-101(National Cheng Kung University): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals.
8 min read
Recombinant Covid-2019 vaccine (Adenovirus type 5 vector)(Hualan Biological Bacterin) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
Recombinant Covid-2019 vaccine (Adenovirus type 5 vector)(Hualan Biological Bacterin): Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review.
8 min read
NG1806 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
NG1806: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
Zelasudil Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
Zelasudil: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
Human Fibroblast Growth Factor 2(Massachusetts Eye and Ear Infirmary) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
Human Fibroblast Growth Factor 2(Massachusetts Eye and Ear Infirmary): Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical.